American Association for Cancer Research
Browse

Supplementary Figure S7 from A Model of Intratumor and Interpatient Heterogeneity Explains Clinical Trials of Curative Combination Therapy for Lymphoma

Download (216.13 kB)
journal contribution
posted on 2025-05-05, 07:20 authored by Amy E. Pomeroy, Adam C. Palmer

Calibration to trials of pola-vedotin in R/R DLBCL and original POLARIX prediction

Funding

National Cancer Institute (NCI)

United States Department of Health and Human Services

Find out more...

National Institute of General Medical Sciences (NIGMS)

United States Department of Health and Human Services

Find out more...

History

ARTICLE ABSTRACT

A new model of intratumor and interpatient heterogeneity in response to drug combinations explains and predicts the results of clinical trials of curative-intent treatments for DLBCL. This model can be used to understand and inform optimal design of curative drug combinations and clinical trials.See related commentary by Goldstein et al., p. 153

Usage metrics

    Blood Cancer Discovery

    Categories

    Keywords

    ChemotherapyCombination chemotherapyComputational MethodsMathematical modelingHematological CancersLymphomasSystems BiologyTumor Heterogeneity

    Licence

    CC BY

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC